The following table provides information about the project.
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III
|Coordinator Country||Spain [ES]|
|Total cost||7˙018˙801 €|
|EC max contribution||5˙998˙786 € (85%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2015-05-01 to 2020-04-30|
Take a look of project's partnership.
|1||FUNDACION CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III||ES (MADRID)||coordinator||1˙465˙972.00|
|2||CHARITE - UNIVERSITAETSMEDIZIN BERLIN||DE (BERLIN)||participant||1˙152˙442.00|
|3||ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI||IT (MILANO)||participant||896˙086.00|
|4||SERVICIO MADRILENO DE SALUD||ES (MADRID)||participant||556˙028.00|
|5||UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU||PL (WROCLAW)||participant||382˙375.00|
|6||CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE BESANCON||FR (BESANCON CEDEX)||participant||374˙309.00|
|8||FERRER INTERNATIONAL||ES (BARCELONA)||participant||263˙574.00|
|9||VSEOBECNA FAKULTNI NEMOCNICE V PRAZE||CZ (PRAHA 2)||participant||242˙125.00|
|10||SEMMELWEIS EGYETEM||HU (BUDAPEST)||participant||238˙500.00|
|11||LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE||UK (LONDON)||participant||96˙750.00|
While Cardiovascular diseases (CVD) are the main cause of death worldwide, they are responsible for half of all deaths in Europe. The overall ageing of the European population and improving survival of patients with coronary heart disease has created a large population of older adults eligible for secondary prevention. Despite the established efficacy of cardiovascular medications, suboptimal adherence reduces their effectiveness and is the primary reason for suboptimal clinical benefit, contributing significantly to worsening of diseases and deaths at the population level. SECURE will be the first trial testing the efficacy of a fixed dose combination (FDC) polypill for secondary cardiovascular prevention in the elderly population (≥ 65 years old). The main objective is to evaluate the potential benefit of the FDC as a component of a cost-effective, globally available and comprehensive treatment strategy for secondary prevention of cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, stroke, and hospitalisation requiring revascularisation) as compared to standard therapy (the three components of the polypill given separately). As part of the secondary endpoints, SECURE will compare the effect of both strategies on adherence and intermediate measures of risk factor control such as lipids and blood pressure. Importantly, it will also measure the pharmacoeconomic impact of the FDC intervention as well as regional differences in all outcomes. The five-year project will thus involve subjects from seven different countries: Spain, Italy, France, Germany, Hungary, Poland and the Czech Republic. The findings and conclusions obtained in SECURE will allow the drafting of clinical guidelines and recommendations that will provide useful guidance and will serve as a reference framework for all stakeholders involved in tackling major challenges related to secondary prevention and treatment of chronic diseases in the elderly population.
Work performed, outcomes and results: advancements report(s)
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SECURE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SECURE" are provided by the European Opendata Portal: CORDIS opendata.
EUROpean clinical validation of a new ex vivo eXpanded stem cell theraPy for cArdiac regeNeration after acute myocarDial infarction: EUROXPANDRead More
Normothermic Perfusion Device for Renal and Hepatic Preservation and Viability AssessmentRead More
DualDur: A Disruptive Diagnostic Technology that Enables for the First Time an Early and Accurate Diagnosis of the tick-borne Lyme Disease.Read More